Allogene Therapeutics ALLO Q1 2026 earnings
Reported May 13, 2026 · After market close
Revenue estimate$2.2K
EPS estimate-$0.19
Next report
Aug 12, 2026 (in a month)Revenue estimate$2.2K
EPS estimate-$0.16
Financials
Q1 2026Valuation & ratios
Versus estimates
Revenue
Diluted EPS
Ask the moment Allogene Therapeutics reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI

Claude
Questions, answered.
- When did Allogene Therapeutics report Q1 2026 earnings?
- Allogene Therapeutics (ALLO) reported Q1 2026 earnings on May 13, 2026 after market close.
- What were Allogene Therapeutics's Q1 2026 revenue and EPS?
- Allogene Therapeutics reported diluted EPS of $-0.18 for Q1 2026.
- Did Allogene Therapeutics beat estimates in Q1 2026?
- EPS beat the consensus estimate of $-0.19 by $0.01.
- How did Allogene Therapeutics's Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, diluted EPS grew 35.7% from $-0.28.
- Where can I find Allogene Therapeutics's Q1 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-034583) and the 10-Q periodic report (0001628280-26-034585) directly on SEC EDGAR. The filing index links above go to sec.gov.